With 98830.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.11 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.57 whereas the lowest price it dropped to was $4.42. The 52-week range on ACHV shows that it touched its highest point at $5.98 and its lowest point at $3.03 during that stretch. It currently has a 1-year price target of $15.56. Beta for the stock currently stands at 1.60.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ACHV was up-trending over the past week, with a rise of 4.30%, but this was down by -4.87% over a month. Three-month performance surged to 1.35% while six-month performance fell -15.28%. The stock lost -23.38% in the past year, while it has gained 8.98% so far this year. A look at the trailing 12-month EPS for ACHV yields -1.13 with Next year EPS estimates of -1.16. For the next quarter, that number is -0.34. This implies an EPS growth rate of 18.58% for this year and 5.02% for next year.
Float and Shares Shorts:
At present, 34.39 million ACHV shares are outstanding with a float of 27.59 million shares on hand for trading. On 2024-11-15, short shares totaled 3.0 million, which was 872.0000000000001 higher than short shares on 1728950400. In addition to Mr. Thomas B. King M.B.A. as the firm’s Executive Chairman, Dr. Richard A. B. Stewart serves as its CEO & Executive Director.
Institutional Ownership:
Through their ownership of 0.59639 of ACHV’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ACHV reported revenue of $0.0 and operating income of -$12466000.0. The EBITDA in the recently reported quarter was -$11744000.0 and diluted EPS was -$0.36.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ACHV since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ACHV analysts setting a high price target of 30.0 and a low target of 10.0, the average target price over the next 12 months is 16.44444. Based on these targets, ACHV could surge 568.15% to reach the target high and rise by 122.72% to reach the target low. Reaching the average price target will result in a growth of 266.25% from current levels.
Analysts have provided yearly estimates in a range of -$1.08556 being high and -$1.33607 being low. For ACHV, this leads to a yearly average estimate of -$1.22125. The surprise factor in the prior quarter was -$0.24. Based on analyst estimates, the high estimate for the next quarter is -$0.31 and the low estimate is -$0.42. The average estimate for the next quarter is thus -$0.35.
